Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 164, Issue 1, Pages 61-72
Publisher
Wiley
Online
2013-10-12
DOI
10.1111/bjh.12599
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
- (2012) A. Sexauer et al. BLOOD
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- (2012) K. Ohashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
- (2011) A. Parmar et al. CANCER RESEARCH
- The bone marrow microenvironment and leukemia: biology and therapeutic targeting
- (2011) Edward Allan R Sison et al. Expert Review of Hematology
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
- (2010) G. Borthakur et al. HAEMATOLOGICA
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
- (2010) K W Pratz et al. LEUKEMIA
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
- (2009) Chunaram Choudhary et al. MOLECULAR CELL
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
- (2008) K. W. Pratz et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens
- (2008) Keith Pratz et al. LEUKEMIA & LYMPHOMA
- Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
- (2008) E. Weisberg et al. MOLECULAR CANCER THERAPEUTICS
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expanding autologous multipotent mesenchymal bone marrow stromal cells
- (2007) Jan E. Brinchmann JOURNAL OF THE NEUROLOGICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now